Suvorexant on Sleep Disturbance in Patients With Chronic Insomnia and Suboptimally Controlled Type 2 Diabetes

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 108 participants.

Also called NCT03818581

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 108 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03818581
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03818581. Randomized; double masking; primary purpose treatment. Start 2019-03-15 (actual); primary completion 2021-11-03 (actual). Results posted on 2023-03-02.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Suvorexant on Sleep Disturbance in Patients With Chronic Insomnia and Suboptimally Controlled Type 2 Diabetes
Condition
Type 2 Diabetes Mellitus
Condition
Insomnia
Condition
Sleep Disorder
Condition
Inflammation
Intervention (Drug)
Suvorexant
Intervention (Other)
Placebo
Lead sponsor
Massachusetts General Hospital (class: other)

Record details

Record id
cardio:ct-nct03818581
Content hash
005e02c23b7604163c33dd4b36c8fafd7c1e2e74b535fd27aa60fa6aa0d51ad4